Loading…
Loading…
[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AstraZeneca
LOS ANGELES--(BUSINESS WIRE)---- $AZN--AZN Investors Have Opportunity to Join AstraZeneca PLC Fraud Investigation with the Schall Law Firm.
Jefferies believes detailed data on AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) experimental lung drug tozorakimab could more than compensate investors for the...
Jefferies believes detailed data on AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) experimental lung drug tozorakimab could more than compensate investors for the recent failure of a separate heart trial. The bank has reiterated its buy rating and 17,500p price target, implying 41% upside from the current 12,380p, and flagged the 8 September presentation at the European Respiratory Society congress as the key catalyst.
Evaluate the expected performance of Astrazeneca (AZN) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Biotech dealmaking has reached a level this year that has already outstripped the whole of 2025, and RBC Capital Markets thinks the pace is unlikely to hold. Cumulative deal value in the first half of 2026 came to $78 billion, against $42 billion for the entirety of last year, according to the bank's half-year sector review.
NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a portion of Neurimmune's royalty interest in AstraZeneca's cliramitug for up to $425 million, including $125 million upfront.
President Donald Trump has announced that all generic drugs imported into the United States would continue to enjoy a zero-percent tariff for another two years, sending major drug stocks up.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for AZN and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.